Bayer’s DAX-Dominating Rally Gets a Valuation Roadmap from BASF’s Planned Agro IPO
Published on 07/13/2026 at 18:07 | Redaktion boerse-global.de
When BASF finally confirmed in recent weeks that it plans to float a minority stake in its agricultural chemicals division as soon as 2027, the headline number turned heads: a prospective enterprise value of €20 billion to €30 billion. That range, reported by Handelsblatt citing financial and company circles, would make the spinoff worth more than half of BASF’s entire current market capitalisation — even though the unit generates barely a sixth of the group’s roughly €60 billion in sales. Yet for investors watching Bayer, the number carries an even more powerful subtext. It provides the first concrete, market-tested yardstick for what Bayer’s own, much larger Crop Science business might be worth if the company ever followed a similar path.
Bayer has never confirmed any plans to spin off or separately list its agro division, but the BASF figure immediately reignited debate among analysts and traders. Crop Science generates significantly more revenue than its BASF counterpart, meaning a comparable valuation multiple would imply a substantial hidden value within Bayer’s conglomerate structure. Speculation about a breakup of the Leverkusen-based group has been a recurring theme ever since the Monsanto acquisition saddled the company with its glyphosate litigation albatross. Now, for the first time, there is a concrete reference point — one that gives fresh ammunition to those arguing that Bayer’s sum-of-the-parts is far higher than the current share price suggests.
The stock itself has already been on a tear. Over the past 30 trading days, Bayer has delivered a total return of 37.3%, the best of any DAX constituent by a wide margin. Qiagen, in second place, managed only 14.1% over the same period, while MTU Aero Engines (13.9%), Beiersdorf (12.1%) and Munich Re (11.0%) round out the top five. The gap is stark enough to suggest a structural re-rating rather than mere sector rotation. At Friday’s close of €50.18, Bayer’s shares had added 31.7% since the start of the year and a staggering 81.3% over the past twelve months — though they have since slipped slightly to around €49.51, still just 7% below the 52-week high of €53.86 reached on July 3.
Should investors sell immediately? Or is it worth buying Bayer?
The immediate trigger for the surge appears to be a marked improvement in the legal risk surrounding the glyphosate lawsuits inherited from the Monsanto deal. Investors have long priced in a “conglomerate discount” driven by the uncertainty of billions of dollars in potential Roundup claims. That discount has been shrinking as court rulings and settlement progress suggest the worst-case scenario is receding. Pipeline advances in the pharmaceuticals division have added further tailwinds, acting as a multiplier effect now that the legal overhang no longer dominates every quarterly earnings call.
Technically, however, the rally has entered overheated territory. With a 14-day Relative Strength Index (RSI) of 67, Bayer is approaching the classic overbought threshold of 70. Its 30-day annualised volatility stands at a punchy 60%, and the share price currently trades 23.9% above its 50-day moving average and a full 31% above the 200-day moving average — a gap so wide that such moves are normally observed only after a fundamental inflection point. The stock already gave back 2.7% over the past seven trading sessions, a sign that profit-taking is creeping in.
For now, the fundamental drivers — shrinking legal clouds, a clearer valuation benchmark from BASF, and a pharma pipeline that is beginning to generate its own momentum — seem robust enough to weather short-term technical corrections. But the overheating signals from Bayer and fellow top-sector performer Beiersdorf (RSI 68.1) suggest that the next leg higher will require either fresh catalysts or a consolidation phase that rebuilds buying power. The BASF spinoff timeline, still dependent on market conditions, is not expected to crystallise until at least 2027, leaving plenty of room for the narrative to evolve between now and then. Whether Bayer’s management chooses to capitalise on the growing investor appetite for an agro carve-out remains the open question that could define the stock’s trajectory through the second half of the year.
Ad
Bayer Stock: New Analysis - 13 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
